Molecular Analysis of Cell Survival and Death Pathways in the Proteasome Inhibitor Bortezomib-resistant PC3 Prostate Cancer Cell Line

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2021 Aug 7

PMID 34363546

Citations 3

Authors

Ertan Kanbur

Ahmet Tarik Baykal

Azmi Yerlikaya

Affiliations

Soon will be listed here.

Abstract

The ubiquitin-proteasome pathway is an important protein quality control system involved in intracellular homeostasis. To achieve intracellular homeostasis, proteins that are misfolded as a result of translational errors or genetic mutations must be eliminated by the ubiquitin-proteasome pathway. In our previous publications, we determined that 4T1 breast and B16F10 melanoma cancer cells have differential levels of resistance to proteasome inhibitors. Again, in the previous studies, we reported that 4T1 cell cultures, despite being p53-mutant, underwent apoptosis as a result of bortezomib treatment. The first goal of this study was to verify the resistance levels of parental and resistant PC3 prostate cancer cells to bortezomib using WST-1 test. As a result of treatment with different bortezomib concentrations for 48 h, the IC value of the parental cells was determined as 32.8 nM and that of the resistant cells was determined as 346 nM. This result showed that the resistant cells were at least 10.5 times more resistant. In addition, to determine whether the resistance gained was reversible or not, the cells were passaged in a medium without bortezomib for one month. The IC value determination by WST-1 test showed that the resistant PC3 cells gained an irreversible bortezomib resistance phenotype. The results of the 3D spheroid experiment showed that the 3D spheroid diameter of resistant cells was significantly higher than that of the parental cells. The studies conducted with Western blot showed that ERK1 MAPK T202 phosphorylation and the conversion of autophagy marker LC3-I to LC3-II were significantly increased in parental cells as compared to the resistant cells. Finally, the results showed that while both maternal embryonic leucine zipper kinase (MELK) inhibitor OTSSP167 and Ca chelator BAPTA-AM (also an inhibitor of the expression of antiapoptotic protein GRP78) are promising agents for cancer cells resistant to the proteasome inhibitors, CDK2 inhibitor CVT-313 was found ineffective in both parental and the resistant cells.

Citing Articles

Label-free nLC-MS/MS proteomic analysis reveals significant differences in the proteome between colorectal cancer tissues and normal colon mucosa.

Zeren S, Seker S, Akgun G, Okur E, Yerlikaya A Med Oncol. 2023; 40(10):298.

PMID: 37707637 DOI: 10.1007/s12032-023-02173-9.

Let's Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer.

Petric T, Sabol M Int J Mol Sci. 2023; 24(6).

PMID: 36982368 PMC: 10049142. DOI: 10.3390/ijms24065293.

Leucine zipper protein 2 serves as a prognostic biomarker for prostate cancer correlating with immune infiltration and epigenetic regulation.

Feng D, Zhu W, Shi X, Wei W, Han P, Wei Q Heliyon. 2022; 8(10):e10750.

PMID: 36217461 PMC: 9547219. DOI: 10.1016/j.heliyon.2022.e10750.

References

Adams J . Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol. 2002; 14(6):628-34. DOI: 10.1097/00001622-200211000-00007. View

Orlowski R, Kuhn D . Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008; 14(6):1649-57. DOI: 10.1158/1078-0432.CCR-07-2218. View

Ciechanover A, Heller H, Elias S, Haas A, Hershko A . ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci U S A. 1980; 77(3):1365-8. PMC: 348495. DOI: 10.1073/pnas.77.3.1365. View

Arlt A, Bauer I, Schafmayer C, Tepel J, Muerkoster S, Brosch M . Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene. 2009; 28(45):3983-96. DOI: 10.1038/onc.2009.264. View

Chen L, Madura K . Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res. 2005; 65(13):5599-606. DOI: 10.1158/0008-5472.CAN-05-0201. View

Stoebner P, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M . High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol. 2005; 152(5):948-53. DOI: 10.1111/j.1365-2133.2005.06487.x. View

Dutaud D, Aubry L, Henry L, Levieux D, Hendil K, Kuehn L . Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Methods. 2002; 260(1-2):183-93. DOI: 10.1016/s0022-1759(01)00555-5. View

Adams J, Kauffman M . Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004; 22(2):304-11. DOI: 10.1081/cnv-120030218. View

Besse A, Besse L, Kraus M, Mendez-Lopez M, Bader J, Xin B . Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. Cell Chem Biol. 2019; 26(3):340-351.e3. DOI: 10.1016/j.chembiol.2018.11.007. View

10.

Escobar M, Velez M, Belalcazar A, Santos E, Raez L . The role of proteasome inhibition in nonsmall cell lung cancer. J Biomed Biotechnol. 2011; 2011:806506. PMC: 3100637. DOI: 10.1155/2011/806506. View

11.

Hideshima T, Richardson P, Chauhan D, Palombella V, Elliott P, Adams J . The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61(7):3071-6. View

12.

Yang H, Zonder J, Dou Q . Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs. 2009; 18(7):957-71. PMC: 3758888. DOI: 10.1517/13543780903002074. View

13.

OConnor O, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M . Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2004; 23(4):676-84. DOI: 10.1200/JCO.2005.02.050. View

14.

Markovic S, Geyer S, Dawkins F, Sharfman W, Albertini M, Maples W . A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer. 2005; 103(12):2584-9. DOI: 10.1002/cncr.21108. View

15.

Yerlikaya A, Yontem M . The significance of ubiquitin proteasome pathway in cancer development. Recent Pat Anticancer Drug Discov. 2012; 8(3):298-309. DOI: 10.2174/1574891x113089990033. View

16.

Lopes U, Erhardt P, Yao R, Cooper G . p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997; 272(20):12893-6. DOI: 10.1074/jbc.272.20.12893. View

17.

MacLaren A, Chapman R, Wyllie A, Watson C . p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ. 2001; 8(3):210-8. DOI: 10.1038/sj.cdd.4400801. View

18.

Boccadoro M, Morgan G, Cavenagh J . Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005; 5(1):18. PMC: 1164423. DOI: 10.1186/1475-2867-5-18. View

19.

Pandit B, Gartel A . Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. Am J Pathol. 2011; 178(1):355-60. PMC: 3069903. DOI: 10.1016/j.ajpath.2010.11.010. View

20.

Yerlikaya A, Okur E, Eker S, Erin N . Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2011; 3(2):333-9. DOI: 10.3892/mmr_00000262. View